Prescribing opioids in renal failure

Journal of Opioid Management

Volumn 3, Issue 6, 2007, Pages 309-315

  Droney, Joanne ^a   Levy, Jeremy ^b   Quigley, Columba ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Creatinine; Glomerular filtration rate; Morphine; Opioid; Renal impairment

Indexed keywords

ALFENTANIL; BUPRENORPHINE; CODEINE; CREATININE; DEXTROPROPOXYPHENE; DIHYDROCODEINE; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; OPIATE; OXYCODONE; TRAMADOL;

ARTICLE; CLINICAL PRACTICE; CONSULTATION; CREATININE BLOOD LEVEL; DRUG CHOICE; GLOMERULUS FILTRATION RATE; HEALTH SURVEY; HUMAN; IRELAND; KIDNEY FAILURE; PHYSICIAN; POSTAL MAIL; PRACTICE GUIDELINE; PRESCRIPTION; QUESTIONNAIRE; UNITED KINGDOM;

EID: 38649115067     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2007.0019     Document Type: Article

References (44)

1. Vainio A, Auvinen A: Prevalence of symptoms among patients with advanced cancer: An international collaborative study. Symptom Prevalence Group. J Pain Symptom Manage. 1996; 12(1): 3-10.
2. Murtagh FE, Ddington-Hall J, Higginson IJ: The prevalence of symptoms in end-stage renal disease: A systematic review. Adv Chronic Kidney Dis. 2007; 14(1): 82-99.
3. Humphreys BD, Soiffer RJ, Magee CC: Renal failure associated with cancer and its treatment: An update. J Am Soc Nephrol. 2005; 16(1): 151-161.
4. Kanuk L, Berenson C: Mail surveys and response rates: A literature review. J Market Res. 1975; XII: 440-453.
5. Maltoni M, Scarpi E, Modonesi C, et al.: A validation study of the WHO analgesic ladder: A two-step vs three-step strategy. Support Care Cancer. 2005; 13(11): 888-894.
6. Conway BR, Fogarty DG, Nelson WE, et al.: Opiate toxicity in patients with renal failure. BMJ. 2006; 332: 345-346.
7. Reid C, Gibbins J, Hanks G: Pain is an issue in renal impairment. BMJ 2006; 332: 488-489.
8. Gibson TP: Renal disease and drug metabolism: An overview. Am J Kidney Dis. 1986; 8(1): 7-17.
9. Chan GL, Matzke GR: Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics. Drug Intell Clin Pharm. 1987; 21: 773-783.
10. Mercadante S, Arcuri E: Opioids and renal function. J Pain. 2004; 5(1): 2-19.
11. Kurella M, Bennett WM, Chertow GM: Analgesia in patients with ESRD: A review of available evidence. Am J Kidney Dis. 2003; 42(2): 217-228.
12. Ashley C, Currie A: The Renal Drug Handbook. 2nd ed. Oxford: Radcliffe Medical, 2004.
13. Murphy EJ: Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intensive Care. 2005; 33(3): 311-322.
14. Murtagh FE, Ddington-Hall JM, Donohoe P, et al.: Symptom management in patients with established renal failure managed without dialysis. EDTNA ERCA J 2006; 32(2): 93-98.
15. Angst MS, Buhrer M, Lotsch J: Insidious intoxication after morphine treatment in renal failure: Delayed onset of morphine-6-glucuronide action. Anesthesiology. 2000; 92(5): 1473-1476.
16. Bickel U, Schumacher OP, Kang YS, et al. Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat. J Pharmacol Exp Ther. 1996; 278(1): 107-113.
17. Osborne R, Joel S, Slevin M: Morphine intoxication in renal failure: The role of morphine-6-glucuronide. Br Med J (Clin Res Ed). 1986; 293: 1101.
18. Talbott GA, Lynn AM, Levy FH, et al.: Respiratory arrest precipitated by codeine in a child with chronic renal failure. Clin Pediatr(Phila) 1997; 36(3): 171-173.
19. Barnes JN, Williams AJ, Tomson MJ, et al.: Dihydrocodeine in renal failure: Further evidence for an important role of the kidney in the handling of opioid drugs. Br Med J (Clin Res Ed). 1985; 290: 740-742.
20. Meuldermans W, Van PA, Hendrickx J, et al.: Alfentanil pharmacokinetics and metabolism in humans. Anesthesiology. 1988; 69(4): 527-534.
21. Chauvin M, Lebrault C, Levron JC, et al.: Pharmacokinetics of alfentanil in chronic renal failure. Anesth Analg. 1987; 66(1): 53-56.
22. Van PA, Vercauteren M, Noorduin H, et al.: Alfentanil kinetics in renal insufficiency. Eur J Clin Pharmacol. 1986; 30(2): 245-247.
23. Baselt RC, Casarett LJ: Biliary and urinary elimination of methadone and its metabolites in the rat. Biochem Pharmacol. 1972; 21: 2704-2712.
24. Kreek MJ, Schecter AJ, Gutjahr CL, et al.: Methadone use in patients with chronic renal disease. Drug Alcohol Depend. 1980; 5(3): 197-205.
25. Inturrisi CE, Colbum WA, Kaiko RF, et al.: Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther. 1987; 41(4): 392-401.
26. Klepstad P, Kaasa S, Cherny N, et al.: Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med. 2005; 19(6): 477-484.
27. McClain DA, Hug CC Jr: Intravenous fentanyl kinetics. Clin Pharmacol Ther. 1980; 28(1): 106-114.
28. Koehntop DE, Rodman JH: Fentanyl pharmacokinetics in patients undergoing renal transplantation. Pharmacotherapy. 1997; 17(4): 746-752.
29. Chambers EJ, Germain M, Brown E: Supportive Care for the Renal Patient. Oxford: Oxford University Press, 2007.
30. Lintz W, Erlacin S, Frankus E, et al.: [Biotransformation of tramadol in man and animal (author's transl)]. Arzneimittelforschung. 1981; 31: 1932-1943.
31. Lotsch J: Opioid metabolites. J Pain Symptom Manage. 2005; 29(5 suppl): S10-S24.
32. Gibson TP: Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCI. Am J Med. 1996; 101(1A): 47S-53S.
33. Kaiko RF, Benziger DP, Fitzmartin RD, et al.: Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther. 1996; 59(1): 52-61.
34. Kirvela M, Lindgren L, Seppala T, et al.: The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth. 1996; 8(1): 13-18.
35. Hand CW, Sear JW, Uppington J, et al.: Buprenorphine disposition in patients with renal impairment: Single and continuous dosing, with special reference to metabolites. Br J Anaesth. 1990; 64(3): 276-282.
36. Ohtani M, Kotaki H, Sawada Y, et al.: Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther. 1995; 272(2): 505-510.
37. Ohtani M, Kotaki H, Nishitateno K, et al.: Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther. 1997; 281(1): 428-433.
38. Filitz J, Griessinger N, Sittl R, et al.: Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain. 2006; 10(8): 743-748.
39. Boger RH: Renal impairment: A challenge for opioid treatment? The role of buprenorphine. Palliat Med. 2006; 20 (suppl 1): S17-s23.
40. Durnin C, Hind ID, Wickens MM, et al.: Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment. Proc West Pharmacol Soc. 2001; 44:81-82.
41. Babul N, Darke AC, Hagen N: Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage. 1995; 10(3): 184-186.
42. Lee MA, Leng ME, Tiernan EJ: Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med. 2001; 15(1): 26-34.
43. Perrone RD, Madias NE, Levey AS: Serum creatinine as an index of renal function: New insights into old concepts. Clin Chem. 1992; 38(10): 1933-1953.
44. Holweger K, Bokemeyer C, Lipp HP: Accurate measurement of individual glomerular filtration rate in cancer patients: An ongoing challenge. J Cancer Res Clin Oncol. 2005; 131: 559-567.